Accendra Health, Inc. logo

Accendra Health, Inc.

ACH

NYSEHealthcareMedical - Distribution

Previous close

$1.20

−$0.11 · -8.40%

Aug 21, 4:00 PM ET

ACH company overview

Historical prices · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

82

Deep Value

Momentum

48

Neutral

Sentiment

59

Mixed

Risk resilience

26

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
US
CEO
Edward A. Pesicka
Listed since
Mar 17, 1980
Employees
6,500

Market position

Day range

Current $1.20

52-week range

Current $1.20

Open
$1.28
Previous close
$1.31
Volume
1.62M
1.54× average
Average volume
1.05M
Average daily volume
Market cap
91.9M USD
Beta
1.61
Market reference 1
50-day average
$2.8618
-58.07% below average
200-day average
$2.7394
-56.19% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.17B USD
P/E (TTM)
-0.31×
P/B (TTM)
-0.17×
P/S (TTM)
0.03×
EV / EBITDA
9.86×
Earnings yield
-511.19%
Free cash flow yield
-140.78%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
44.83%
Operating margin
3.62%
Net margin
-11.41%
Return on equity
238.76%
Return on assets
-44.89%
Return on invested capital
12.33%

Financial health

Debt / equity
-3.23×
Current ratio
0.58×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends55%21%-14%-49%Gross margin, FY2021: 15.46%Gross margin, FY2022: 18.35%Gross margin, FY2023: 20.56%Gross margin, FY2024: 20.74%Gross margin, FY2025: 46.68%Operating margin, FY2021: 3.77%Operating margin, FY2022: 1.44%Operating margin, FY2023: 1.01%Operating margin, FY2024: -1.94%Operating margin, FY2025: 8.03%Net margin, FY2021: 2.26%Net margin, FY2022: 0.22%Net margin, FY2023: -0.40%Net margin, FY2024: -3.39%Net margin, FY2025: -39.85%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 15.46%. Gross margin FY2022 18.35%. Gross margin FY2023 20.56%. Gross margin FY2024 20.74%. Gross margin FY2025 46.68%. Operating margin FY2021 3.77%. Operating margin FY2022 1.44%. Operating margin FY2023 1.01%. Operating margin FY2024 -1.94%. Operating margin FY2025 8.03%. Net margin FY2021 2.26%. Net margin FY2022 0.22%. Net margin FY2023 -0.40%. Net margin FY2024 -3.39%. Net margin FY2025 -39.85%.

Income trends

Revenue

2.76B USD-74.19%

Operating income

221.74M USD+429.51M USD

Net income

−1.1B USD-203.47%
Income trends across reported periods11.88B USD7.16B USD2.44B USD−2.28B USDRevenue, FY2021: 9.79B USDRevenue, FY2022: 9.96B USDRevenue, FY2023: 10.33B USDRevenue, FY2024: 10.7B USDRevenue, FY2025: 2.76B USDOperating income, FY2021: 368.47M USDOperating income, FY2022: 142.91M USDOperating income, FY2023: 104.51M USDOperating income, FY2024: −207.77M USDOperating income, FY2025: 221.74M USDNet income, FY2021: 221.59M USDNet income, FY2022: 22.39M USDNet income, FY2023: −41.3M USDNet income, FY2024: −362.69M USDNet income, FY2025: −1.1B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.79B USD. Revenue FY2022 9.96B USD. Revenue FY2023 10.33B USD. Revenue FY2024 10.7B USD. Revenue FY2025 2.76B USD. Operating income FY2021 368.47M USD. Operating income FY2022 142.91M USD. Operating income FY2023 104.51M USD. Operating income FY2024 −207.77M USD. Operating income FY2025 221.74M USD. Net income FY2021 221.59M USD. Net income FY2022 22.39M USD. Net income FY2023 −41.3M USD. Net income FY2024 −362.69M USD. Net income FY2025 −1.1B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.76B USD10.7B USD10.33B USD9.96B USD9.79B USD
Cost of goods sold1.47B USD8.48B USD8.21B USD8.13B USD8.27B USD
Gross profit1.29B USD2.22B USD2.13B USD1.83B USD1.51B USD
Research and development12.1M USD
Selling, general, and administrative1.07B USD1.91B USD1.81B USD1.55B USD1.08B USD
Operating expenses1.07B USD2.43B USD2.02B USD1.68B USD1.14B USD
Interest expense107.18M USD143.8M USD157.92M USD128.89M USD48.09M USD
Depreciation and amortization214.52M USD264.78M USD287.38M USD228.67M USD90.62M USD
Operating income221.74M USD−207.77M USD104.51M USD142.91M USD368.47M USD
Net income−1.1B USD−362.69M USD−41.3M USD22.39M USD221.59M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
-4.25%
11 comparable reports
Latest EPS result
-0.19
Estimate -0.08 · Miss by 126.65%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.610.320.04-0.25Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 0.55, estimate 0.53, surprise +3.77%, Beat. Q2 2025, reported May 8, 2025: actual 0.23, estimate 0.2, surprise +15.00%, Beat. Q3 2025, reported Aug 11, 2025: actual 0.26, estimate 0.27, surprise -3.70%, Miss. Q4 2025, reported Oct 30, 2025: actual 0.25, estimate 0.23, surprise +8.70%, Beat. Q1 2026, reported Feb 19, 2026: actual 0.21, estimate 0.22, surprise -4.55%, Miss. Q2 2026, reported May 11, 2026: actual -0.04, estimate -0.06, surprise +33.33%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.19, estimate -0.084, surprise -126.65%, Miss. Q4 2026, reported Oct 29, 2026: actual —, estimate -0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.91B2.11B1.32B521.22MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 28, 2025: actual 2.7B USD, estimate 2.68B USD, surprise +0.78%, Beat. Q2 2025, reported May 8, 2025: actual 2.63B USD, estimate 2.74B USD, surprise -3.80%, Miss. Q3 2025, reported Aug 11, 2025: actual 681.92M USD, estimate 2.37B USD, surprise -71.28%, Miss. Q4 2025, reported Oct 30, 2025: actual 697.26M USD, estimate 714.79M USD, surprise -2.45%, Miss. Q1 2026, reported Feb 19, 2026: actual 708.97M USD, estimate 713.43M USD, surprise -0.63%, Miss. Q2 2026, reported May 11, 2026: actual 627.8M USD, estimate 644.18M USD, surprise -2.54%, Miss. Q3 2026, reported Aug 10, 2026: actual 613.2M USD, estimate 628.66M USD, surprise -2.46%, Miss. Q4 2026, reported Oct 29, 2026: actual —, estimate 619.39M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

6 institutions
Leerink PartnersmaintainMarket Perform
JP MorganmaintainUnderweight
B of A SecuritiesmaintainUnderperform

ACH news

ACH peers

ETFs holding ACH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ACH

research.disclaimer